The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain

Ivanova, Jasmina; Birnbaum, Howard G.; Yushkina, Y.; Sorg, Rachael; Reed, John Chip; Merchant, Sanjay

doi:10.5055/jom.2013.0165

Cited by 23 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,21 One study of the six studies that was conducted for ORADEs in outpatients did report the prevalence of specific events; however, the health care costs were summative and not specific to one type of ADE. 23 This evaluation was conducted to build upon previous studies of claims data that may be bias towards more severe events. Patients were surveyed to identify self-reported ORADEs; in addition, claims …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Cost of Opioid-Related Adverse Drug Events

Kane‐Gill¹,

Rubin²,

Smithburger³

et al. 2014

Journal of Pain & Palliative Care Pharmacotherapy

View full text Add to dashboard Cite

Opioids are the cornerstone of pain management; however, their use is associated with a variety of adverse drug events (ADEs) ranging from nausea and vomiting to urinary retention and respiratory depression. The purpose of this review is to describe the frequency and cost associated with different types of opioid-related ADEs to better understand their economic impact. A search of studies published in journals from 1946 to December, 2013, was conducted using MEDLINE and EMBASE. A total of 20 articles were reviewed. Data reflect a substantial economic burden of opioid-related ADEs resulting in high hospital costs, prolonged hospital stays, and substantial health care resource usage. Nausea, vomiting, and constipation are frequent and increased costs occur in all types of pain (surgical, nonsurgical, cancer, noncancer) in both inpatients and outpatients. Given the large economic burden of opioid-related ADEs, prevention rather than treatment may be the most effective strategy.

show abstract

Section: Resultsmentioning

confidence: 99%

“…This may be especially true for patients receiving chronic opioid therapy for pain management beyond the inpatient setting. 23 Additionally, the large volume of studies evaluating the cost of constipation compared with other ADEs gives us a better understanding of its financial impact.…”

Section: Discussionmentioning

confidence: 99%

The Cost of Opioid-Related Adverse Drug Events

Kane‐Gill¹,

Rubin²,

Smithburger³

et al. 2014

Journal of Pain & Palliative Care Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Today, many pain physicians probably would not insist on a prior therapeutic attempt with highly potent opioids, and SCS would be ranked in the therapeutic order between weak and strong opioids. At any rate, the disadvantages of long-term opioid therapy125 should be weighed against those of SCS therapy. SCS can certainly be used together with analgetic medications, but in an optimal setting, SCS can make pain medication redundant.…”

Section: Long-term Outcomes and Place In Therapymentioning

confidence: 99%

Spinal cord stimulation for neuropathic pain: current perspectives

Wolter¹

2014

JPR

View full text Add to dashboard Cite

Neuropathic pain constitutes a significant portion of chronic pain. Patients with neuropathic pain are usually more heavily burdened than patients with nociceptive pain. They suffer more often from insomnia, anxiety, and depression. Moreover, analgesic medication often has an insufficient effect on neuropathic pain. Spinal cord stimulation constitutes a therapy alternative that, to date, remains underused. In the last 10 to 15 years, it has undergone constant technical advancement. This review gives an overview of the present practice of spinal cord stimulation for chronic neuropathic pain and current developments such as high-frequency stimulation and peripheral nerve field stimulation.

show abstract

“…[10, 11] Individuals were classified as having PMR if they fulfilled the 2012 American College of Rheumatology classification criteria for PMR. [7] Exclusion criteria included the presence of other conditions that could lead to similar symptoms, such as rheumatoid arthritis, systemic lupus erythematosus, polymyositis, multiple myeloma, fibromyalgia or chronic infection. A comparison cohort of subjects without PMR with similar age, sex, and indexed to calendar year of PMR diagnosis of the patients with PMR was drawn randomly from the same population.…”

Section: Methodsmentioning

confidence: 99%

“…[3–6] Opioid use has also been associated with increased healthcare cost and substantial economic burden stemming from overdose and misuse. [7, 8]…”

Section: Introductionmentioning

confidence: 99%

THU0630 Opioid use in patients with polymyalgia rheumatica

Achenbach¹,

Zamora-Legoff

Crowson³

et al. 2017

Poster Presentations

View full text Add to dashboard Cite

Objective To examine the trends of chronic opioid use in patients with polymyalgia rheumatica (PMR) over an 11 year period in Olmsted County, Minnesota, USA and compare use to subjects without the disease. Methods Retrospective data on opioid prescriptions were collected from 2005 to 2015 in a population-based incidence cohort of patients meeting the 2012 American College of Rheumatology classification criteria for PMR alongside comparison subjects. Poisson regression methods were used to compare opioid use between these groups. Results 244 patients with PMR and 211 non-PMR comparator subjects were included in the study. Rates of chronic opioid use were not significantly different between the two groups. 7.5% of patients with PMR were identified as chronic users by the end of the study period compared with 5.2% of non-PMR subjects. Any opioid use was also not significantly higher in PMR, with relative risk of 1.10 (95% CI 0.97, 1.26, p=0.14). Rates of chronic use among patients over 80 years were higher in both groups. Conclusion Patients with PMR do not appear to have higher rates of opioid use compared with the general population.

show abstract

The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain

Abstract: Prevalence of opioid-related side effects among patients with CNCP who initiated opioids was substantially higher based on patient survey than from charts or claims. Opioid-related side effects were associated with significantly higher healthcare costs.

Cited by 23 publications

References 0 publications

The Cost of Opioid-Related Adverse Drug Events

The Cost of Opioid-Related Adverse Drug Events

Spinal cord stimulation for neuropathic pain: current perspectives

THU0630 Opioid use in patients with polymyalgia rheumatica

Contact Info

Product

Resources

About